CONCERNING OF ACHIEVEMENT COMPENSATION OF TYPE 2 DIABETES MELLITUS

Authors

  • Romanova I. P. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Chernyavska I. V. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Gonharova O. A. Kharkiv Postgraduate Medical Academy
  • Oleinikova S. P. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Kholodniy A. V. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Gasanova H. A. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Kravchun N. A. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2014.2.03

Keywords:

type 2 diabetes, carbohydrate metabolism, lipid metabolism, «Glimaks®», glimepiride

Abstract

It was studied the clinical effectiveness and was evaluated the safety of anti-diabetic drug of sulfonylureas third-generation «Glimaks®» in patients with type 2 diabetes. After three months of treatment were assessed indicators of carbohydrate and lipid metabolism, the influence on functional state of the liver and kidneys. It was found the positive hypoglycemic effect of «Glimaks®», a tendency to decrease of total cholesterol, triglycerides, low-density lipoprotein, very low density lipoprotein, increased high-density lipoprotein, good tolerance, no negative influence on the functional state of the liver and kidneys.

References

Pan’kiv VI. Mezhdunar Jendokrinol Zhurn 2011;6(38):52-57.

Koshiba K, Nomuro M, Nakaya Y, et al. J Med Invest 2006; 53:87-94.

Kaminskij AV. Mezhdunar Jendokrinol Zhurn 2010;1:46-47.

Poltorak VV, Gorshunskaja MJu. Liky Ukrai’ny 2010; 6(142):82-85.

Poltorak VV, Gorbenko NI. Ukr Terapevtych Zhurn 2001; 3(2):27-32.

Yunukai K, Watanabe M, Nakashima Y, et al. Biochem Byophys Res Commun 2005; 328:484-490.

Kaminskij AV. Mezhdunar Jendokrinol Zhurn 2011; 2(34):59-62.

DeFronzo RA. Diabetologia 2010; 53:1270-1287.

Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care 2009; 32:193-203.

Spravochnik po laboratornoj diagnostike SINJeVO, pod red. Nebyl’covoj OV, Kiev, 2013:644 p.

Schiekofer S, Rudofsky G, Andrassy M, et al. Diabetes Obes Metab 2003; 5:251-261.

Kravchun NA, et al. Primenenie amarila v kompleksnoj terapii saharnogo diabeta tipa 2 s metabolicheskim sindromom, Har’kov, 2004:20 p.

Kravchun NO, et al. Suchasna peroral’na antydiabetychna terapija, Harkiv, 2007:20 p.

Kravchun NO, et al. Efektyvnist’ glimepirydu v real’nij klinichnij praktyci u hvoryh na cukrovyj diabet 2 typu, Harkiv, 2012:18 p.

Briscoe VJ, Griffith ML, Davis SN. Expert Opin Drug Metab Toxicol 2010; 6:225-235.

Zuev KA, Pan’kiv VI. Mezhdunar Jendokrinol Zhurn 2011; 2(34):46-50.

Shustov SB, Romashevskij BV, Lysenko AG. Saharnyj Diabet 2001; 4: 42-45.

Astahova AV, Lepahin VK. Lekarstva. Neblagoprijatnye pobochnye reakcii i kontrol’ bezopasnosti,Moskva, 2008:256 p.

Downloads

Published

2014-05-22

How to Cite

Romanova, I. P., Chernyavska, I. V., Gonharova, O. A., Oleinikova, S. P., Kholodniy, A. V., Gasanova, H. A., & Kravchun, N. A. (2014). CONCERNING OF ACHIEVEMENT COMPENSATION OF TYPE 2 DIABETES MELLITUS. Problems of Endocrine Pathology, 48(2), 22-29. https://doi.org/10.21856/j-PEP.2014.2.03

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 3 4 > >>